2024 Theodore D. Veru Symposium
Artificial Intelligence - The Catalyst for Business and Health Care Innovation
On Wednesday, April 10, Dan Veru, Senior Partner and CIO at Palisade Capital Management, led an exciting discussion about Artificial Intelligence - The Catalyst for Business and Health Care Innovation, joined by speakers Lisa Chai, General Partner at Interwoven Ventueres, and Sean Ianchulev, Chairman and Founder at Eyenovia. Following the discussion was a networking reception.
Featured Speakers
Dan Veru
Dan is a Senior Partner and serves as Palisade Capital Management’s Chief Investment Officer. He is also Chairman of the firm's Investment and ESG Committees and a member of our Operating Committee. In this capacity, he has oversight responsibilities for all of Palisade’s investment strategies that trade publicly traded securities. Dan became associated with Palisade’s founders in 1984 at Drexel Burnham Lambert and later at Smith Barney, where he held a variety of analytical positions. From 1992 through 1999, he was President and Director of Research at Awad Asset Management, a division of Raymond James & Associates. Dan rejoined his colleagues at Palisade in 2000, and was later promoted to Chief Investment Officer. A graduate of Franklin & Marshall College, Dan has appeared as a guest on CNBC, Bloomberg News, and Fox News. He also contributes market opinions to various financial publications.
Lisa Chai
Lisa brings two decades of experience investing in disruptive technology companies including artificial intelligence and robotics. Prior to founding Interwoven Ventures, Lisa was a Managing Partner at ROBO Global Ventures & Senior Analyst and Portfolio Manager at ROBO Global Investments where she helped launch Artificial Intelligence index fund as well as the Healthcare Technology and Innovation fund. Prior to joining ROBO Global, Lisa was a Senior Vice President of Research for Palisade Capital, responsible for the technology sector and Senior Vice President at Angelo, Gordon & Co. Earlier in her career, she served as a Portfolio Manager for Tavistock Group (PE fund) and a Partner at Ridgecrest Partners. Lisa currently serves as a board member and strategic advisor to various AI leaders in machine vision, mobility and autonomy.
Sean Ianchulev, MD MPH
Dr. Ianchulev is a Harvard-trained physician-executive, ophthalmic surgeon, inventor and serial entrepreneur, who has been at the forefront of medical innovation and products that have transformed the ophthalmic field and are impacting medical care for hundreds of thousands of patients every year. While at Genentech, Dr. Ianchulev headed the ophthalmology clinical research group and directed the development and the FDA approval of Lucentis®, one of the most successful biotech innovations in the field of ophthalmology with more than $4B of annual sales. Dr. Ianchulev is also a Professor at the Icahn School of Medicine at Mount Sinai.
About the Veru Symposium
For a quarter century, the Theodore D. Veru Symposium has brought world-renowned business and public leaders to campus to provide students, faculty, staff, and the public access to esteemed thought leaders.
The Veru Symposium was created by University of Hartford Barney School of Business alumnus Peter Veru '85 in commemoration of his father, Theodore. This revered symposium has brought some of the world's best marketers, economists, analysts, and investors to campus to share their knowledge and expertise.